Lara Longpre Net Worth

The estimated Net Worth of Lara Longpre is at least $7.17 Milhão dollars as of 2 February 2024. Ms. Longpre owns over 847 units of Mirum Pharmaceuticals Inc stock worth over $4,375,697 and over the last 5 years she sold MIRM stock worth over $115,699. In addition, she makes $2,681,960 as Chief Development Officer at Mirum Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms. Longpre MIRM stock SEC Form 4 insiders trading

Lara has made over 5 trades of the Mirum Pharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently she sold 847 units of MIRM stock worth $22,183 on 2 February 2024.

The largest trade she's ever made was selling 1,019 units of Mirum Pharmaceuticals Inc stock on 8 January 2024 worth over $28,573. On average, Lara trades about 284 units every 94 days since 2019. As of 2 February 2024 she still owns at least 104,407 units of Mirum Pharmaceuticals Inc stock.

You can see the complete history of Ms. Longpre stock trades at the bottom of the page.

Lara Longpre biography

Lara Longpre serves as Chief Development Officer of the Company. where she leads our development operations, program management and alliance management. Previously, Ms. Longpre served as Chief Operating Officer at Flashlight from November 2017. From September 2014 to June 2018, Ms. Longpre served as Chief Operating Officer of MedGenesis Therapeutix Inc. (“MedGenesis”), a biopharmaceutical company, where she was responsible for program management, alliance management, clinical operations, technical operations, and business operations. Prior to that, Ms. Longpre held multiple positions at Jennerex from April 2008 to May 2015, including Chief Operating Officer from July 2010 to May 2014. Before joining Jennerex, Ms. Longpre was Senior Vice-President, Clinical and Corporate Affairs at MedGenesis, where she was responsible for business operations including the intellectual property portfolio, corporate files and operating plans. She also previously held several leadership roles with PRA International and CroMedica including operations, regulatory affairs, and proposals and contracts. Ms. Longpre received a B.A. in biology from Cornell University, a M.M.S. from Harvard Medical School and an MBA from Queen’s University in Ontario, Canada.

What is the salary of Lara Longpre?

As the Chief Development Officer of Mirum Pharmaceuticals Inc, the total compensation of Lara Longpre at Mirum Pharmaceuticals Inc is $2,681,960. There are 2 executives at Mirum Pharmaceuticals Inc getting paid more, with Christopher Peetz having the highest compensation of $6,235,180.

How old is Lara Longpre?

Lara Longpre is 50, she's been the Chief Development Officer of Mirum Pharmaceuticals Inc since 2018. There are 9 older and 9 younger executives at Mirum Pharmaceuticals Inc. The oldest executive at Mirum Pharmaceuticals Inc is Michael Grey, 67, who is the Chairman of the Board.

What's Lara Longpre's mailing address?

Lara's mailing address filed with the SEC is C/O MIRUM PHARMACEUTICALS, INC., 950 TOWER LANE, SUITE 1050, FOSTER CITY, CA, 94404.

Insiders trading at Mirum Pharmaceuticals Inc

Over the last 5 years, insiders at Mirum Pharmaceuticals Inc have traded over $10,912,565 worth of Mirum Pharmaceuticals Inc stock and bought 7,735,045 units worth $117,972,829 . The most active insiders traders include Forest Baskett, Scott D Sandell, eAnthony A. Jr. Florence. On average, Mirum Pharmaceuticals Inc executives and independent directors trade stock every 24 days with the average trade being worth of $4,538,937. The most recent stock trade was executed by Patrick J Heron on 6 September 2024, trading 230 units of MIRM stock currently worth $9,563.

What does Mirum Pharmaceuticals Inc do?

mirum pharmaceuticals, inc., a biopharmaceutical company, focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. its lead product candidate is maralixibat, an investigational oral drug that is in phase 3 clinical trial for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of alagille syndrome and biliary atresia disease. the company is also develops volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. mirum pharmaceuticals, inc. was founded in 2018 and is headquartered in foster city, california.

Complete history of Ms. Longpre stock trades at Mirum Pharmaceuticals Inc

Mirum Pharmaceuticals Inc executives and stock owners

Mirum Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Christopher Peetz,
  President, Chief Executive Officer, Director
• Michael Grey,
  Chairman of the Board
• Lara Longpre,
  Chief Development Officer
• Pamela Vig,
  Chief Scientific Officer
• Christopher Peetz,
  Pres, CEO & Director
• Dr. Ian Clements,
  Chief Financial Officer
• Peter Radovich M.B.A., Ph.D.,
  Chief Operating Officer
• Laurent Fischer,
  Independent Director
• Laura Brege,
  Independent Director
• Niall ODonnell,
  Independent Director
• Edward Mathers,
  Independent Director
• Patrick Heron,
  Independent Director
• Tiba Aynechi,
  Director
• Edwin Tucker,
  Chief Medical Officer
• Ian Clements,
  Chief Financial Officer
• Vinita P. Kumar,
  Sr. vice Pres of Quality
• Lara Longpre MBA, MSC,
  Chief Devel. Officer
• Dr. Pamela Vig Ph.D.,
  Head of R&D
• Erin Campany,
  Sr. VP of HR
• Dr. Edwin Jonathan Tucker M.D.,
  Chief Medical Officer
• Paul K. Ross,
  Chief Compliance Officer
• Lara Longpre MSC, MBA,
  Chief Devel. Officer
• Carol L Brosgart,
  Director
• Holdings A/S Novo,
  10% owner
• Mohamad Makhzoumi,
  10% owner
• Niall O'donnell,
  Director
• Peter W. Sonsini,
  10% owner
• Anthony A. Jr. Florence,
  10% owner
• Ali Behbahani,
  10% owner
• Forest Baskett,
  10% owner
• Joshua Makower,
  10% owner
• David M Mott,
  10% owner
• Paul Edward Walker,
  10% owner
• Life Sciences Ix, L.P.Fhmls...,
  
• Carmen Chang,
  10% owner
• Scott D Sandell,
  10% owner
• Peter J Barris,
  10% owner
• Enterprise Associates 16, L...,
  
• James E Deerfield Mgmt Hif,...,
  
• Enterprise Associates 16, L...,
  10% owner
• William Fairey,
  
• Timothy P Walbert,
  
• Joanne Quan,
  CHIEF MEDICAL OFFICER
• Saira Ramasastry,
  
• James E Deerfield Mgmt Hif,...,
  
• Lon Cardon,
  
• Partners 16, L.P.Nea 16 Gp,...,
  
• Jolanda Howe,
  SVP, GLOBAL CONTROLLER
• Eric Bjerkholt,
  CHIEF FINANCIAL OFFICER
• Peter Radovich,
  PRESIDENT AND COO